Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.

Division of Oncology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
Oncogene (Impact Factor: 8.56). 06/2007; 26(20):2950-4. DOI: 10.1038/sj.onc.1210095
Source: PubMed

ABSTRACT The t(2;5) chromosomal translocation occurs in anaplastic large-cell lymphoma arising from activated T lymphocytes. This genomic rearrangement generates the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncoprotein that is a chimeric protein consisting of parts of the nuclear protein NPM and ALK receptor protein-tyrosine kinase. We used yeast two-hybrid screening to identify an adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT)-2 as a new partner that interacted with the cytoplasmic domain of ALK. Immunoprecipitation assay revealed that SNT-1 and SNT-2 interacted with NPM-ALK and kinase-negative NPM-ALK mutant. Y156, Y567 and a 19-amino-acid sequence (aa 631-649) of NPM-ALK were essential for this interaction. The interaction through Y156 and Y567 was dependent on phosphorylation of these tyrosines, whereas the interaction through the 19-amino-acid sequence was independent of phosphorylation. NPM-ALK mutant protein mutated at these three binding sites showed significantly reduced transforming activity. This transformation-defective NPM-ALK mutant still interacted with signal transducing proteins such as phospholipase C-gamma and phosphatidylinositol 3-kinase, which were previously reported to be relevant to NPM-ALK-dependent tumorigenesis. These observations indicate that the three SNT-binding sites of NPM-ALK are important for its transforming activity. This raises a possibility that SNT family proteins play significant roles in cellular transformation triggered by NPM-ALK, which though remains to be verified.

  • [Show abstract] [Hide abstract]
    ABSTRACT: NPM-ALK chimeric oncogene is aberrantly expressed in an aggressive subset of T-cell lymphoma that frequently occurs in children and young adults. The mechanisms underlying the oncogenic effects of NPM-ALK are not completely elucidated. Inducible nitric oxide synthase (iNOS) promotes the survival and maintains the malignant phenotype of cancer cells by generating NO, a highly active free radical. We tested the hypothesis that iNOS is deregulated in NPM-ALK(+) T-cell lymphoma and promotes the survival of this lymphoma. In line with this possibility, an iNOS inhibitor and NO scavenger decreased the viability, adhesion and migration of NPM-ALK(+) T-cell lymphoma cells, and an NO donor reversed these effects. Moreover, the NO donor salvaged the viability of lymphoma cells treated with ALK inhibitors. In further support of an important role of iNOS, we found iNOS protein to be highly expressed in NPM-ALK(+) T-cell lymphoma cell lines and in 79% of primary tumours but not in human T lymphocytes. Although expression of iNOS mRNA was identified in NPM-ALK(+) T-cell lymphoma cell lines and tumours, iNOS mRNA was remarkably elevated in T lymphocytes, suggesting posttranscriptional regulation. Consistently, we found that miR-26a contains potential binding sites and interacts with the 3'-UTR of iNOS. In addition, miR-26a was significantly decreased in NPM-ALK(+) T-cell lymphoma cell lines and tumours compared with T lymphocytes and reactive lymph nodes. Restoration of miR-26a in lymphoma cells abrogated iNOS protein expression and decreased NO production and cell viability, adhesion, and migration. Importantly, the effects of miR-26a were substantially attenuated when the NO donor was simultaneously used to treat lymphoma cells. Our investigation of the mechanisms underlying the decrease in miR-26a in this lymphoma revealed novel evidence that STAT3, a major downstream substrate of NPM-ALK tyrosine kinase activity, suppresses MIR26A1 gene expression.
    The Journal of Pathology 05/2013; 230(1). DOI:10.1002/path.4171 · 7.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Activation of the Anaplastic Lymphoma Kinase (ALK) RTK is a key oncogenic mechanism in a growing number of tumour types. In the majority of cases ALK is activated by fusion with a dimerising partner protein as a result of chromosomal translocation events, most studied in the case of the nucleophosmin (NPM)-ALK and EML4-ALK oncogenes. It is now also appreciated that the full length ALK receptor can be activated by point mutations and by deletions within the extracellular domain, such as those observed in neuroblastoma. Several studies have employed phosphoproteomics approaches to find substrates of ALK fusion proteins. In this study we have used mass spectrometry-based phosphotyrosine profiling to characterize phosphotyrosine signaling events associated with the full length ALK receptor. A number of previously identified as well as novel targets were identified. One of these, STAT3, has previously been observed as activated in response to oncogenic ALK signaling, but the significance of this in signaling from the full length ALK receptor has not been explored further. We show here that activated ALK robustly activates STAT3 on Y705 in a number of independent neuroblastoma cell lines. Furthermore, knockdown of STAT3 by RNAi resulted in a reduction of MYCN protein levels downstream of ALK signaling. These observations, together with a decreased level of MYCN and inhibition of neuroblastoma cell growth in the presence of STAT3 inhibitors, suggest that activation of STAT3 is important for ALK signaling activity in neuroblastoma. This article is protected by copyright. All rights reserved.
    FEBS Journal 01/2013; 280(21):5269 - 5282. DOI:10.1111/febs.12453 · 3.99 Impact Factor
  • Article: Frs2 alpha
    AfCS-Nature Molecule Pages 01/2009; DOI:10.1038/mp.a000967.01


Available from